Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”), of the important July 6, 2021 lead plaintiff deadline. SO WHAT: If you purchased ChemoCentryx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N

CCXI INVESTOR NEWS: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – CCXI

RADNOR, Pa., May 18, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds ChemoCentryx, Inc. (NASDAQ:  CCXI) ("ChemoCentryx") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021 , inclusive (the "Class Period").

CCXI INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

NEW YORK--(BUSINESS WIRE)-- #CCXI--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline

New York, New York--(Newsfile Corp. - May 15, 2021) - WHY:Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than...

CCXI Investor Notice: Rosen, A Leading Law Firm, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - CCXI

Radnor, Pennsylvania--(Newsfile Corp. - May 15, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period").Investor Reminder: Investors who purchased or acquired ChemoCentryx common stock during the Class Period may,...

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds ChemoCentryx, Inc. Shareholders of Securities Fraud Class Action Lawsuit

San Francisco, California--(Newsfile Corp. - May 13, 2021) - Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. Class Period: Nov. 26, 2019 - May 3, 2021Lead Plaintiff Deadline: July 6, 2021Visit: www.hbsslaw.com/investor-fraud/CCXIContact An Attorney Now: CCXI@hbsslaw.com844-916-0895ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx

CCXI INVESTORS ACT NOW: Contact Hagens Berman, National Trial Attorneys, to Recover Losses Due to Alleged Securities Fraud

RADNOR, Pa., May 12, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021 , inclusive (the "Class Period").

Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

OAKLAND, Calif.--(BUSINESS WIRE)---- $CCXI #CCXI--Gibbs Law Group LLP investigates potential legal claims on behalf of ChemoCentryx investors.

Lost Money in ChemoCentryx, Inc.?

San Francisco, California--(Newsfile Corp. - May 12, 2021) - Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. Class Period: Nov. 26, 2019 - May 3, 2021Lead Plaintiff Deadline: July 6, 2021Visit: www.hbsslaw.com/investor-fraud/CCXIContact An Attorney Now: CCXI@hbsslaw.com844-916-0895ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ChemoCentryx (CCXI) Investors to Securities Class Action, Encourages Investors with Losses to Contact the Firm

Radnor, Pennsylvania--(Newsfile Corp. - May 11, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired ChemoCentryx common stock during the Class Period may,...

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for ChemoCentryx, Inc. Investors in Securities Fraud Class Action Lawsuit

NEW YORK, May 11, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ChemoCentryx securities between November 26, 2019 and May 3, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ccxi.

CCXI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ChemoCentryx, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

San Francisco, California--(Newsfile Corp. - May 11, 2021) - Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims.Class Period: Nov. 26, 2019 - May 3, 2021Lead Plaintiff Deadline: July 6, 2021Visit: www.hbsslaw.com/investor-fraud/CCXIContact An Attorney Now: CCXI@hbsslaw.com844-916-0895ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action: The lawsuit focuses on ChemoCentryx'

CCXI CLASS ACTION FILED: Contact HAGENS BERMAN to Recover Losses Due to Alleged Securities Fraud

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) common stock between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). ChemoCentryx investors have until July 6, 2021 to file a lead plaintiff motion. If you suffered a loss on your C

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

NEW YORK, May 10, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

CCXI INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - CCXI

BENSALEM, Pa.--(BUSINESS WIRE)---- $CCXI #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) common stock between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). ChemoCentryx investors have until July 6, 2021 to file a lead plaintiff motion. Investors suffering losses on their ChemoCentryx investments are encouraged to contact the Law Offices of Howa

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

SAN DIEGO--(BUSINESS WIRE)-- #CCXIstock--The suit alleges defendants issued false statements concerning ChemoCentryx business and prospects, resulting in its stock trading at inflated prices.

Notice of Lead Plaintiff Deadline for Shareholders in the ChemoCentryx, Inc. Class Action Lawsuit

After a critical FDA briefing doc, the advisory committee split 9-9 on efficacy, 10-8 on safety and risk-benefit. This tells me a CRL is likely because the FDA has no reason to go against its own briefing document and break the tie.

ChemoCentryx: CRL Likely

Radnor, Pennsylvania--(Newsfile Corp. - May 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired ChemoCentryx common stock during the Class Period may,...

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - CCXI

SAN DIEGO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $CCXI--Shareholder rights law firm Robbins LLP announces that a purchaser of ChemoCentryx, Inc. (NASDAQ: CCXI) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between November 26, 2019 and May 3, 2021. ChemoCentryx is biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer

SHAREHOLDER ALERT: Robbins LLP Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders

RADNOR, Pa.--(BUSINESS WIRE)---- $CCXI #classaction--Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

ChemoCentryx Inc (NASDAQ: CCXI) tanked roughly 60% in the stock market on Friday as approval for its drug for an autoimmune disease hung in the balance. ChemoCentryx is seeking FDA approval for Avacopan as a treatment for Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV).

Here's why ChemoCentryx plunged 60% in the stock market on Friday

Investors aren't optimistic after an FDA advisory committee vote for avacopan.

Why ChemoCentryx Stock Is Cratering Again Today

ChemoCentryx (NASDAQ: CCXI) shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated vasculitis. The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate to support approval.

Why ChemoCentryx Shares Are Plunging Today

Yesterday, the FDA's Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for ChemoCentryx Inc's (NASDAQ: CCXI) avacopan. After going over time, they ended up without consensus.

Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges

Shares of ChemoCentryx Inc. tumbled 61.7% in trading on Friday, the day after a Food and Drug Administration advisory committee voted 10-8 that the benefits of the company's experimental autoimmune drug, avacopan, outweigh the risks. The mixed response from committee members followed critical words from the FDA earlier this week that had sent ChemoCentryx's stock diving.

News for Chemocentryx Stock (CCXI)